<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373827</url>
  </required_header>
  <id_info>
    <org_study_id>SST2011-2</org_study_id>
    <nct_id>NCT01373827</nct_id>
  </id_info>
  <brief_title>Protocol To Evaluate Patient Measurements After Ultrasonic Treatment</brief_title>
  <official_title>Protocol To Evaluate Patient Measurements After Ultrasonic Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Surgical Technologies, LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sound Surgical Technologies, LLC.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients enrolled in this study will come from the Investigator's patient population and be
      ordinarily suitable for treatment using the MC1 device. The treatment they receive will be no
      different if they participate than if they do not. The study is only to observe the patients
      before, during and after their usual treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">7</enrollment>
  <condition>Patients Treated With VaserShape MC1</condition>
  <arm_group>
    <arm_group_label>MC1 Subjects</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VASERShape MC1</intervention_name>
    <description>Use of the VASERShape MC1 device as part of routine practice</description>
    <arm_group_label>MC1 Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects presenting to the investigator for treatment using the MC1 are potential study
        candidates and will be screened for eligibility. Every effort will be made to establish
        eligibility of the participants before enrollment. Subjects who do not meet all
        inclusion/exclusion criteria will not be enrolled. Enrollment in the study occurs at the
        time the patient is randomized to the assigned treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Female between 20 and 50 years of age, inclusive, on the day of enrolment.

          2. Has a BMI between 20 and 30 kg/m2.

          3. Is to be treated in the posterior thigh / saddlebag area using the MC1.

          4. Has never been treated with the MC1 before.

          5. Females who are post menopausal or using a medically acceptable form of birth control
             prior to study enrollment and during the course of the study. (i.e., condoms with
             spermicide, oral contraceptives contraceptive implants etc.)

        Exclusion Criteria:

          1. Subject is lactating, has a positive pregnancy test within 7 days of planned study
             procedure (for female subjects of child-bearing potential), or intends to become
             pregnant during the study.

          2. Currently enrolled in another device or drug study that has not completed the required
             follow-up period, or has completed all other study-required follow-up less than 30
             days before enrolment in this study.

          3. Keloid scars, hypertorphic scars or a history of abnormal healing.

          4. Any known bruising disorder, anticoagulative / thromboembolic condition , hemorrhagic
             (bleeding) status or use of anti coagulants.

          5. Tissue ischemia in the area to be treated.

          6. Suffering from concurrent conditions such as liver or kidney disorders, Hypertension
             or abnormally high blood pressure.

          7. High cholesterol and/or diabetes.

          8. Active collagen vascular disease (e.g. fibromyalgia, panniculitis, lupus etc.).

          9. Epilepsy.

         10. Tuberculosis.

         11. Auxiliary electric organs (such as pacemakers), metal or myoelectric prosthesis.

         12. Suffering from Endocrine syndromes or thyroid hyperfunction.

         13. Active skin infection, any infection in the treated area within the last 30 days or
             skin disease in the area to be treated (e.g. eczema, psoriasis, urticaria,
             dermographism).

         14. Bone, muscle or joint disease, dysfunction or healing in the area to be treated.

         15. Malignancy in the area to be treated.

         16. Laminectomy in the area to be treated.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>Roy G Geronemus, MD</name_title>
    <organization>Laser &amp; Skin Surgery Center of New York</organization>
  </responsible_party>
  <keyword>VASER</keyword>
  <keyword>VASERShape</keyword>
  <keyword>MC1</keyword>
  <keyword>ultrasound</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

